Onesource Specialty Pharma Limited
ONESOURCE · ISIN: INE013P01021
Onesource Specialty Pharma Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE013P01021.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.06%), NIFTY SC 250 TRI (0.55%)
CHART
Onesource Specialty Pharma Limited - growth of ₹100
Growth of ₹100 invested on 2025-10-31, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
+3.15%
3M
-3.09%
6M
-9.69%
1Y
-14.36%
3Y CAGR
-
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Onesource Specialty Pharma Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-09-10 | SHORT_SELL | 5 |
| 2026-09-09 | SHORT_SELL | 5 |
Frequently asked questions
What is Onesource Specialty Pharma Limited's 1-year and 3-year return?
Onesource Specialty Pharma Limited's 1-year price return is -14.36%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Onesource Specialty Pharma Limited's latest financial performance?
Onesource Specialty Pharma Limited's trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹2,133 Cr, with a TTM profit after tax of ₹23 Cr and an EBITDA margin of 7.36%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹2.03.
What is Onesource Specialty Pharma Limited's quality score?
Onesource Specialty Pharma Limited has a Punji quality score of 16.7 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Onesource Specialty Pharma Limited's technical indicators show?
As of 2026-10-29, Onesource Specialty Pharma Limited's RSI (14-day) is 59.06 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently below its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Onesource Specialty Pharma Limited?
As of 2026-09-30, Onesource Specialty Pharma Limited's shareholding is split across Promoter (30.47%), Public (69.53%). Promoter holding of 30.47% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Onesource Specialty Pharma Limited part of any major market index?
Yes - Onesource Specialty Pharma Limited is a constituent of NIFTY 500 TRI (0.06% weight) and NIFTY SC 250 TRI (0.55% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
Has Onesource Specialty Pharma Limited seen any recent bulk or block deals?
Yes, as of 2026-09-10 - the most recent recorded deal was a SHORT_SELL on 2026-09-10 for 5 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns